Related references
Note: Only part of the references are listed.Sustained Alpha-Sarcoglycan Gene Expression after Gene Transfer in Limb-Girdle Muscular Dystrophy, Type 2D
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2010)
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype
Niek P. van Til et al.
BLOOD (2010)
Progress and prospects: immune responses to viral vectors
S. Nayak et al.
GENE THERAPY (2010)
Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease
Baodong Sun et al.
JOURNAL OF GENE MEDICINE (2010)
CRIM-negative infantile Pompe disease: 42-month treatment outcome
Marianne Rohrbach et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Priya S. Kishnani et al.
MOLECULAR GENETICS AND METABOLISM (2010)
Evaluation of Systemic Follistatin as an Adjuvant to Stimulate Muscle Repair and Improve Motor Function in Pompe Mice
Joseph W. Foley et al.
MOLECULAR THERAPY (2010)
Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease
Baodong Sun et al.
MOLECULAR THERAPY (2010)
Gel-mediated Delivery of AAV1 Vectors Corrects Ventilatory Function in Pompe Mice With Established Disease
Cathryn S. Mah et al.
MOLECULAR THERAPY (2010)
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
Paul A. LoDuca et al.
CURRENT GENE THERAPY (2009)
AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS
Mark E. Hester et al.
CURRENT GENE THERAPY (2009)
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
Marc Nicolino et al.
GENETICS IN MEDICINE (2009)
Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer
Mario Cooper et al.
HUMAN GENE THERAPY (2009)
Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses
Roberto Calcedo et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells
S. Nayak et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Impact of the Underlying Mutation and the Route of Vector Administration on Immune Responses to Factor IX in Gene Therapy for Hemophilia B
Ou Cao et al.
MOLECULAR THERAPY (2009)
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease
N. A. M. E. Van der Beek et al.
NEUROMUSCULAR DISORDERS (2009)
Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
Nancy J. Mendelsohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer - Implications for Antigen Presentation and Immunotoxicity
Ashley T. Martino et al.
PLOS ONE (2009)
Neural deficits contribute to respiratory insufficiency in Pompe disease
Lara R. DeRuisseau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Mark L. Brantly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
A. Joseph et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice
Robin J. Ziegler et al.
HUMAN GENE THERAPY (2008)
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice
Richard L. Sidman et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Correction of multiple striated muscles in murine Pompe diseasethrough adeno-associated virus-mediated gene therapy
Baodong Sun et al.
MOLECULAR THERAPY (2008)
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions
Pedro R. Lowenstein et al.
CURRENT GENE THERAPY (2007)
Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors
Cathryn Mah et al.
MOLECULAR THERAPY (2007)
Recombinant human acid α-glucosidase -: Major clinical benefits in infantile-onset Pompe disease
P. S. Kishnani et al.
NEUROLOGY (2007)
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Haiyan Jiang et al.
MOLECULAR THERAPY (2006)
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo
Christina A. Pacak et al.
CIRCULATION RESEARCH (2006)
Pompe disease diagnosis and management guideline
Priya S. Kishnani et al.
GENETICS IN MEDICINE (2006)
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease
Priya S. Kishnani et al.
JOURNAL OF PEDIATRICS (2006)
Diagnostic challenges for Pompe disease: An under-recognized cause of floppy baby syndrome
RR Howell et al.
GENETICS IN MEDICINE (2006)
Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors
C Mah et al.
GENE THERAPY (2005)
Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter
BD Sun et al.
MOLECULAR THERAPY (2005)
Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II
KO Cresawn et al.
HUMAN GENE THERAPY (2005)
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II
BD Sun et al.
MOLECULAR THERAPY (2005)
Pompe disease in infants and children
PS Kishnani et al.
JOURNAL OF PEDIATRICS (2004)
A new method for recombinant adeno-associated virus vector delivery to murine diaphragm
C Mah et al.
MOLECULAR THERAPY (2004)
Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease
M Rucker et al.
DEVELOPMENT (2004)
Long term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk
JMP Van den Hout et al.
PEDIATRICS (2004)
Enzyme replacement therapy in the mouse model of Pompe disease
N Raben et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors
TJ Fraites et al.
MOLECULAR THERAPY (2002)
Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2
C Martini et al.
NEUROLOGY (2001)
Intercellular transfer of the virally derived precursor form of acid α-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease
DF Pauly et al.
HUMAN GENE THERAPY (2001)
Share Paper
